

March 10, 2025



Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System

MINNEAPOLIS, March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.

Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run, offering 4x the throughput of the Jess™ Simple Western System and 5x faster turn-around-times than Sally Sue™ and Peggy Sue™ Simple Western Systems. Leo also provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Additionally, Leo features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance.

"With Leo, scientists can achieve their development milestones faster and more efficiently, completing studies with fewer runs, operators and instruments," commented Will Geist, President of Bio-Techne's Protein Sciences Segment. "Leo will enable our customers to accelerate their cutting-edge science and bring next generation therapies to market faster."

Early adopters have been thrilled with the power that Leo brings, with beta testers praising the instrument's robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays, recombinant protein expression and more.

Explore Leo's capabilities at bio-technne.com/leo. Data on Leo's performance will be presented at an upcoming webinar. Registration details can be found [here](#).

[About Bio-Techne Corporation](#) (NASDAQ: TECH)

Contact: David Clair, Vice President, Investor Relations & Corporate Development

david.clair@bio-technne.com

612-656-4416



View original content to download multimedia:<https://www.prnewswire.com/news-releases/bio-techne-begins-shipping-leo---a-next-generation-high-throughput-simple-western-system-302395190.html>

SOURCE Bio-Techne Corporation